Management of lipid abnormalities in patients with diabetes

Sillars, A. and Sattar, N. (2019) Management of lipid abnormalities in patients with diabetes. Current Cardiology Reports, 21(11), 147. (doi: 10.1007/s11886-019-1246-1) (PMID:31758270) (PMCID:PMC6874523)

[img]
Preview
Text
199961.pdf - Published Version
Available under License Creative Commons Attribution.

599kB

Abstract

Purpose of Review: To describe lipid abnormalities in diabetes, when they occur and the evidence base for lipid management with established and new drugs to prevent diabetes complications. We also discuss how to manage statin intolerance. Recent Findings: Statins remain first-line therapy in patients with diabetes, though newer therapies to reduce LDL-C have emerged, including ezetimibe as an add-on therapy to statins, and injectable PCSK9 inhibitors, both of which are safe and effective in diabetes. Emerging evidence suggests a need to consider lipid-lowering therapies more often in younger patients with both type 1 and type 2 diabetes. Summary: Statins remain the cornerstone of lipid management in diabetes but other options are increasing. There is also now evidence for better managing apparent statin intolerance. Notably, younger patients lose the most life years from their diabetes, an observation that future guidelines need to consider.

Item Type:Articles
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Sillars, Dr Anne and Sattar, Professor Naveed
Authors: Sillars, A., and Sattar, N.
College/School:College of Medical Veterinary and Life Sciences > Institute of Cardiovascular and Medical Sciences
Journal Name:Current Cardiology Reports
Publisher:Springer
ISSN:1523-3782
ISSN (Online):1534-3170
Published Online:22 November 2019
Copyright Holders:Copyright © The Authors 2019
First Published:First published in Current Cardiology Reports 21(11):147
Publisher Policy:Reproduced under a Creative Commons license

University Staff: Request a correction | Enlighten Editors: Update this record